{"id":"catapresan-tts-2","safety":{"commonSideEffects":[{"rate":"40","effect":"Dry mouth"},{"rate":"33","effect":"Drowsiness"},{"rate":"16","effect":"Dizziness"},{"rate":"10","effect":"Constipation"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Fatigue"},{"rate":"15","effect":"Skin irritation at patch site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clonidine is a central-acting alpha-2 adrenergic agonist that binds to presynaptic alpha-2 receptors in the brainstem, reducing the release of norepinephrine and decreasing overall sympathetic outflow. This leads to reduced peripheral vascular resistance and lower heart rate, resulting in decreased blood pressure. The transdermal formulation (TTS) provides sustained drug delivery over several days.","oneSentence":"Clonidine reduces blood pressure by stimulating alpha-2 adrenergic receptors in the brain, decreasing sympathetic nervous system activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:31.480Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT00421863","phase":"PHASE4","title":"Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study","status":"COMPLETED","sponsor":"Heart Care Foundation","startDate":"2005-02","conditions":"Hypertension","enrollment":1111},{"nctId":"NCT01082874","phase":"PHASE3","title":"PeriOperative ISchemic Evaluation-2 Trial","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2010-07","conditions":"Cardiovascular Disease","enrollment":10010},{"nctId":"NCT01559012","phase":"PHASE3","title":"Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum","status":"COMPLETED","sponsor":"A.O.U. Città della Salute e della Scienza","startDate":"2012-02","conditions":"Hyperemesis Gravidarum","enrollment":13},{"nctId":"NCT00860925","phase":"PHASE4","title":"PeriOperative ISchemic Evaluation-2 Pilot","status":"COMPLETED","sponsor":"McMaster University","startDate":"2009-05","conditions":"Cardiovascular Disease","enrollment":90}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"CARDIAC FAILURE"},{"count":5,"reaction":"EJECTION FRACTION DECREASED"},{"count":5,"reaction":"RESPIRATORY ACIDOSIS"},{"count":3,"reaction":"ANAEMIA"},{"count":3,"reaction":"HYPERTENSIVE CRISIS"},{"count":2,"reaction":"BRADYCARDIA"},{"count":2,"reaction":"CONFUSIONAL STATE"},{"count":2,"reaction":"DRUG INEFFECTIVE"},{"count":2,"reaction":"DYSPNOEA"},{"count":2,"reaction":"FACE OEDEMA"}],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Catapresan TTS 2","genericName":"Catapresan TTS 2","companyName":"Heart Care Foundation","companyId":"heart-care-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clonidine reduces blood pressure by stimulating alpha-2 adrenergic receptors in the brain, decreasing sympathetic nervous system activity. Used for Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}